|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||393.83 - 399.75|
|52-week range||308.57 - 411.44|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||21.41|
|Forward dividend & yield||9.78 (2.67%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemicThe acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instrumentsTIB Molbiol will continue to focus on the research and development of assays that rapidly address critical healthcare needs including biological threats Basel, 1 December 2021 - Roche (SIX: RO
Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.